ZA200803370B - Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into middle ear - Google Patents

Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into middle ear

Info

Publication number
ZA200803370B
ZA200803370B ZA200803370A ZA200803370A ZA200803370B ZA 200803370 B ZA200803370 B ZA 200803370B ZA 200803370 A ZA200803370 A ZA 200803370A ZA 200803370 A ZA200803370 A ZA 200803370A ZA 200803370 B ZA200803370 B ZA 200803370B
Authority
ZA
South Africa
Prior art keywords
prevention
treatment
methods
drug delivery
nonionic surfactants
Prior art date
Application number
ZA200803370A
Other languages
English (en)
Inventor
Neil E Paulsen
Roland H Johnson
William R Campbell
Original Assignee
Piedmont Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piedmont Pharmaceuticals Llc filed Critical Piedmont Pharmaceuticals Llc
Publication of ZA200803370B publication Critical patent/ZA200803370B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA200803370A 2005-09-26 2006-08-25 Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into middle ear ZA200803370B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72053605P 2005-09-26 2005-09-26

Publications (1)

Publication Number Publication Date
ZA200803370B true ZA200803370B (en) 2009-09-30

Family

ID=37900209

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200803370A ZA200803370B (en) 2005-09-26 2006-08-25 Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into middle ear

Country Status (11)

Country Link
US (1) US20080318918A1 (fr)
EP (1) EP1931388A4 (fr)
JP (1) JP2009509956A (fr)
CN (1) CN101272807A (fr)
AU (1) AU2006295248A1 (fr)
BR (1) BRPI0616415A2 (fr)
CA (1) CA2622002A1 (fr)
EA (1) EA200800950A1 (fr)
IL (1) IL190079A0 (fr)
WO (1) WO2007037886A2 (fr)
ZA (1) ZA200803370B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8271101B2 (en) * 2007-08-29 2012-09-18 Advanced Bionics Modular drug delivery system for minimizing trauma during and after insertion of a cochlear lead
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
CA2721927C (fr) 2008-04-21 2014-01-28 Otonomy, Inc. Preparations auriculaires de traitement de maladies et etats otiques
CN102026623B (zh) 2008-05-14 2013-08-14 奥德纳米有限公司 用于治疗耳部病症的控制释放皮质类固醇组合物和方法
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
WO2010011466A2 (fr) 2008-06-27 2010-01-28 Otonomy, Inc. Compositions de modulation du snc à libération contrôlée et procédés de traitement des troubles otiques
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US10092580B2 (en) 2008-07-21 2018-10-09 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US11033624B2 (en) 2010-06-02 2021-06-15 Novaflux Inc. Medical item for prevention and treatment of ear infection
MD674Z (ro) * 2013-03-07 2014-04-30 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Metodă de tratament al otitei medii exudative la copii
US10166146B2 (en) 2013-03-08 2019-01-01 Mark Mitchnick Ear medication dispenser with sensor
CA2921816A1 (fr) 2013-08-27 2015-03-05 Otonomy, Inc. Methodes pour le traitement de troubles otiques chez les enfants
WO2015168642A1 (fr) 2014-05-02 2015-11-05 Labib Mohamed E Dispositif de libération de médicament pouvant être utilisé dans des cavités corporelles muqueuses
WO2018053173A1 (fr) 2016-09-16 2018-03-22 Otonomy, Inc. Formulations de gel otique pour le traitement de l'otite externe

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549770A (en) * 1963-12-09 1970-12-22 Crown Zellerbach Corp Therapeutic administration of effective amounts of dimethyl sulfoxide to human and animal subjects
US5231112A (en) * 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
US4897269A (en) * 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
DE3936328A1 (de) * 1989-10-27 1991-05-02 Schering Ag Pharmazeutische praeparate
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6093417A (en) * 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
US6723714B2 (en) * 1999-07-06 2004-04-20 Blansett Pharmacal Co., Inc. Aqueous solvent for corticosteroids
WO2001015677A2 (fr) * 1999-08-31 2001-03-08 Alcon Laboratories, Inc. Utilisation d'agonistes de 5-ht1b/1d pour le traitement des douleurs oculaires
CA2425749A1 (fr) * 2000-09-25 2002-04-04 Daniel Ciszewski Combinaisons microbiennes pour l'oreille destinees au traitement d'animaux dont la membrane du tympan est dechiree
US6716813B2 (en) * 2000-11-28 2004-04-06 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
JP2006510657A (ja) * 2002-12-06 2006-03-30 アライバ ファーマシューティカルズ，インコーポレイティド 中耳炎の処置のための方法および組成物
MXPA05010659A (es) * 2003-04-04 2005-12-12 Merial Ltd Formulaciones veterinarias antihelminticas topicas.
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
EP1784164A4 (fr) * 2004-09-03 2008-07-09 Piedmont Pharmaceuticals Llc Methodes de traitement et de prevention transmembranaires de l'otite moyenne
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use

Also Published As

Publication number Publication date
EP1931388A4 (fr) 2010-12-15
WO2007037886B1 (fr) 2008-01-10
US20080318918A1 (en) 2008-12-25
CA2622002A1 (fr) 2007-04-05
EA200800950A1 (ru) 2008-08-29
EP1931388A2 (fr) 2008-06-18
WO2007037886A3 (fr) 2007-10-25
WO2007037886A2 (fr) 2007-04-05
AU2006295248A1 (en) 2007-04-05
IL190079A0 (en) 2008-08-07
BRPI0616415A2 (pt) 2011-06-21
JP2009509956A (ja) 2009-03-12
CN101272807A (zh) 2008-09-24

Similar Documents

Publication Publication Date Title
ZA200803370B (en) Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into middle ear
ZA200803367B (en) Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate transmembrane drug delivery into the middle ear
EP1861161A4 (fr) Appareil et methode permettant de distribuer des agents therapeutiques et/ou autres a l'oreille interne et a d'autres tissus
EP1784164A4 (fr) Methodes de traitement et de prevention transmembranaires de l'otite moyenne
PL2444079T3 (pl) Kompozycje i sposoby leczenia chorób oczu
IL196108A0 (en) Active agent formulations, methods of making, and methods of use
GB2444688B (en) Motorized flosser and method of use
EP2007398A4 (fr) Vitesses d'administration élevées pour préparations médicamenteuses lipidiques et méthodes de traitement associées
IL184735A0 (en) Pharmaceutical formulations and methods of use
EP2209371A4 (fr) Compositions et procédés pour le traitement de la rétinopathie diabétique
EP2293800A4 (fr) Compositions et procédés pour le traitement de troubles de l'oreille
HK1213814A1 (zh) 雙氯芬酸製劑和使用方法
ZA200710983B (en) Bacterial cellulose-containing formulations and method of producing effective bacterial cellulose-containing formulations
EP1945170A4 (fr) Procede et appareil de traitement d'acouphenes a frequence predominante
EP2019646A4 (fr) Méthode, dispositif et système d'administration de substances thérapeutiques dans l'oeil
HK1171972A1 (zh) 治療疾病的方法和產品
GB2445651B (en) Well treatment products and methods of using them
ZA200903653B (en) Methods for treatment of cochlear and vestibular disorders
ZA201004861B (en) Prevention and treatment of otitis media using iga enriched milk
IL194066A0 (en) Therapeutic composition for treatment of tinnitus
EP1976551A4 (fr) Compositions comprenant des cristaux de proteines complexes par des polycations et procede de traitement associe
EP1930321A4 (fr) Procédé de synthèse de dérivés tétrasubstitués de 5-azaspiro[2.4]-heptane et intermédiaires optiquement actifs dudit procédé
ZA200704725B (en) Product and method of treatment
ZA200806876B (en) Crystal form of besipirdine chlorhydrate, process preparation and use thereof
GB0710651D0 (en) Ear and nose cleaning apparatus which can be used as earplug